The Future of Retatrutide Dosing Retatrutide remains in Phase III clinical trials, and final FDA-approved dosing guidelines will likely evolve as additional long-term data emerges
Combining exercise and dietary changes has a multiplicative effect on weight loss with a similar trend in lipids
A Phase 1 clinical trial of the MOTS-C analog CB4211 found the compound safe after 7 days of dosing, though persistent mild injection site bumps were noted
However, some studies have reported contradictory evidences
How are payors and providers balancing the high upfront costs of GLP-1s with delayed realization of long-term health benefits in value-based care models?
Ethics declarations Conflict of interest SC received lecture or consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk